Immunohistochemical and SSCP analysis of p53 in Malignant Lymphomas

Journal of Korean Medical Science

Volumn 13, Issue 4, 1998, Pages 361-368

  Park, Chan Kum ^a   Lee, Jung Dal ^a  

^a Hanyang University   (South Korea)

Author keywords

Genes, p53; Herpesvirus 4, human; Lymphoma; Protein, p53

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; ENZYME IMMUNOASSAY; FEMALE; GENETICS; HUMAN; IN SITU HYBRIDIZATION; LYMPHOMA; MALE; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; STAINING;

ADOLESCENT; ADULT; BLOTTING, SOUTHERN; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; LYMPHOMA; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; STAINING AND LABELING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032130389     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.1998.13.4.361     Document Type: Article

References (48)

1. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453-6.
2. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699-703.
3. Porter PL, Gown AM, Kramp SG, Coltrera MD. Wide spread p53 overexpression in human malignant tumors. Am J Pathol 1992; 140: 145-53.
4. Chang F, Syrjanen S, Tervahauta A, Syrjanen K. Tumorigenesis associated with the p53 tumor suppressor gene. Br J Cancer 1993; 68: 653-61.
5. Caron de Fromentel C, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chrom Cancer 1992; 4: 1-15.
6. Momand J, Zambetti GP, Oslon DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-45.
7. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 1992; 357: 82-4.
8. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath I, Knowles DM, Dalla-Favera R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad USA 1991; 88: 5413-7.
9. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82: 1994-2004.
10. Villuendas R, Piris MA, Orradre JL, Mollejo M, Algara P, Sanchez L, Martinez JC, Martinez P. p53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 1992; 166: 235-41.
11. Said JW, Barrera R, Shintaku IP, Nakamura H, Koeffler HP. Immunohistochemical analysis of p53 expression in malignant lymphomas. Am J Pathol 1992; 141: 1343-8.
12. Niedobitek G, Rowlands DC, Young LS, Herbst H, Williams A, Hall P, Padfield J, Rooney N, Jones EL. Overexpression of p53 in Hodgkin's disease: lack of correlation with Epstein-Barr virus infection. J Pathol 1993; 169: 207-12.
13. Soini Y, Paakko P, Alavaikko M, Vahakangas K. p53 expression in lymphatic malignancies. J Clin Pathol 1992;45:1011-4.
14. Cesarman E, Inghirami G, Chadbum A, Knowles DM. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 1993; 143: 845-56.
15. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79: 7824-7.
16. Lenoir GM. Role of the virus, chromosomal translocation and cellular oncogenes in the etiology of Burkitt's lymphoma. In: the Epstein-Barr virus: recent advances. Epstein MA, Achong BG, eds. London: William Heinemann, 1986: 183-205.
17. Takada K, Shimizu N, Tanabe-Tochikura A, Kuroiwa Y. Pathogenic role of Epstein-Barr virus in human cancer. Intervirology 1995; 38: 214-20.
18. Park CK, Ko YH. Detection of EBER nuclear RNA in T-cell lymphomas involving the skin-an in situ hybridization study. Br J Dermatol 1996; 134: 488-93.
19. Farrell P, Allan GJ, Shanahan F, Vousden KH, Crook T. p53 is frequently mutated in Burkitt's lymphoma cell lines. Embo J 1991; 10: 2879-87.
20. Cherney BW, Bhatia KG, Sgadari C, Gutierrez MI, Mostowski H, Pike SE, Gupta G, Magrath IT, Tosato G. Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. Cancer Res 1997; 57: 2508-15.
21. Pezzella F, Morrison H, Jones M, Gatter KC, Lane D, Harris AL, Mason DY. Immunohistochemical detection of p53 and bcl-2 proteins in non Hodgkin's lymphoma. Histopathology 1993; 22: 39-44.
22. Korkolopoulous P, Oates J, Kittas HP. p53 in hematologic malignancies. Blood 1994; 84: 2412-21.
23. Lee JH, Lee SS, Park JS, Lee S, Yang MH, Yoon TY. Altered p53 expression in Epstein-Barr virus positive T cell lymphomas. J Korean Med Sci 1995; 10: 399-405.
24. Matsushima AY, Cesarman E, Chadburn A, Knowles DM. Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 1994; 144: 573-84.
25. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989; 5: 874-9.
26. Kim EK, Park CK, Kong G, Park MH, Lee JD. Alteration of tumor suppressor gene in hyperplastic lesions and adenocarcinomas of uterine endometrium. Korean J Pathol 1997; 31: 662-71.
27. Hurlimann J, Saraga EP. Expression of p53 protein in gastric carcinomas. Am J Surg Pathol 1994; 18: 1247-53.
28. Leahy DT, Salman R, Mulcathy H, Sheahan K, O'Donoghue DP, Parfrey NA. Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 1996; 180: 364-70.
29. Harris AL. p53 expression in human breast cancer. Adv Cancer Res 1992; 59: 69-88.
30. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, Halperin AJ, Baden HP, Shapiro PE, Bale AE, Brash DE. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 1993; 90: 4216-20.
31. Kennedy SM, Macgeogh C, Jaffe R, Spurr NK. Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol 1994; 25: 438-42.
32. Gannon JV, Greaves R, Lane DP. Activating mutations in p53 produce a common confirmational effect. A monoclonal antibody specific for the mutant form. Embo J 1990; 9: 1595-602.
33. Reihaus E, Kohler M, Kraiss S, Oren M, Montenarh M. Regulation of the level of the oncoprotein p53 in non transformed and transformed cells. Oncogene 1990; 5: 137-45.
34. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc 70-p53 complex with an altered half life. Mol Cell Biol 1988; 8: 531-9.
35. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142: 1534-43.
36. Baas IO, Mulder JWR, Offerhaus JA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172: 5-12.
37. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
38. Sarkar FH, Kupsky WJ, Li Y-W, Sreepathi P. Analysis of p53 gene mutations in human gliomas by polymerase chain reaction-based single-strand confirmation polymorphism and DNA sequencing. Diagn Mol Pathol 1994; 3: 2-8.
39. Burmer GC, Rabinovitch PS, Loeb LA. Analysis of c-Ki-ras mutations in human colon carcinoma by cell sorting, polymerase chain reaction and DNA sequencing. Cancer Res 1989; 49: 2141-6.
40. Mietz JA, Unger T, Huibregtse JM, Howley PM. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. Embo J 1992; 11: 5013-20.
41. Keiss TD, Slebos RJ, Nelson WG, Kastan KB, Plunkett BS, Han SM, Lorincz AT, Hedrick L, Cho KR. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 1993; 90: 3988-92.
42. Luka J, Jornvall H, Klein G. Purification and biochemical characterization of the Epstein-Barr virus determined nuclear antigen and an associated protein with a 53,000-dalton subunit. J Virol 1980; 35: 592-602.
43. Niedobitek G, Agathanggelou A, Barber P, Smallman LA, Jones EL, Young LS. p53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J Pathol 1993; 170: 457-61.
44. Spruck III CH, Tsai YC, Huang DP, Yang AS, Rideout III WM, Gonzalez-Zulueta M, Choi P, Lo KW, Yu MC, Jones PA. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 1992; 52: 4787-90.
45. Wrede D, Tidy JA, Crook T, Lane D, Vousden KH. Expression of RB and p53 proteins in HPV-positive and HPV-negative cervical carcinoma cell lines. Mol Carcinog 1991; 4: 171-5.
46. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumors. Lancet 1992; 339: 1070-3.
47. Harada S, Yanagi K. Aminoacid sequence homology of Epstein-Barr virus nuclear antigen-2 to adenovirus E1A, human papillomavirus-16 E7 and SV40 large T antigen in the functional domains for growth transformation. Oncogene 1991; 6: 461-2.
48. Wiman KG, Magnusson KP, Ramqvist T, Klein G. Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAB240. Oncogene 1991; 6: 1633-9.